Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine

Cain, David J; del Arroyo, Ana Gutierrez; Ackland, Gareth L

doi:10.1186/2197-425X-2-6

Intensive Care Medicine Experimental

Table 6 Demographic information of lymphocyte apoptosis studies

From: Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine

Author	Age			Gender (%male)			Ethnicity	Severity of subject disease			Subject drug exposure documentation
Author	Subjects	Controls	Statistical test result	Subjects	Controls	Statistical test result	Ethnicity	Index	Score	No. of groups	Sedatives	Antibiotics	Steroids
Roger [43]	63 (37 to 82)	55 (37 to 5)	0.04	50	43	0.76	N	SAPS II	55 (12 to 92)	2	N	Y t	Y t
Bandyopadhyay [58]	?	'Matched’	N	?	'Matched’	N	N	APACHE	>21	1	N	N	N
White [11]	54 (72 to 80)	Bacteraemia: 73 (70 to 82)	>0.05	52	Bacteraemia 40	>0.05	Y	APACHE	25 (21 to 28)	2	N	N	N
White [11]	64 ± 2	65 ± 1	0.74	68	70	0.86	N			2	N	N	N
Zhang [44]	58 ± 4	59 ± 4	N	52	50	N	N	APACHE II	26 ± 3	1	N	Y t	Y t
Guignant [45]	63 (54 to 73)	?	N	68	N	N		SAPS II	53(39 to 64)	1	N	N	Y t
Vaki [46]	71 ± 2	?	N	54	?	N	N	APACHE II	20 ± 9	1 (3)	N	N	N
Slotwinski [62]	62 ± 9; 63 ± 9	-	N	5, 50	-	N	N	TNM	?	1	N	Y t	N
Gogos [47]	67 ± 17; 68 ± 20; 54 ± 25; 64 ± 16		P < 0.0001	52, 62, 57, 67, 64		P = 0.011	N	APACHE II	12 ± 7; 16 ± 9; 13 ± 8; 18 ± 8; 20 ± 5	3	N	N	N
Hoogerwerf [48]	57 ± 5,	66 ± 5	N* (p < 0.0001)	63	50	N	N	APACHE II	19 ± 2	1	N	N	N
Yousef [49]	44 ± 9	45 ± 9, 44 ± 10	N	59	60, 57	N	N	SOFA	12 (7 to 14)	3 (5)	N	N	N
Turrel-Davin [50]	60 ± 4	'Age matched’	N	63	'Sex matched’	N	N	SAPS II	51 ± 3	1	N	N	Y
Pelekanou [51]	69 ± 16	64 ± 20	0.099	64	43	0.300	N	APACHE II	18 ± 4; 15 ± 5	1	N	N	Y
Papadima [61]	66 ± 7; 67 ± 10		0.8	85, 47		0.54	N	ASA	I to II	1	Y t	Y t	Y t
Delogu [52]	?	?	N	?	?	N	N	?	?	1	N	N	N
Weber [53]	56 ± 4	61 ± 5,?	>0.05	68, 80	?	N	N	SAPS II	26 ± 2	1	N	N	Y
Roth [54]	56 ± 6	52 ± 14	N	66	'Matched’	N	N	APACHE	N/S	1	N	N	N
Le Tulzo [55]	55 ± 4; 64 ± 4	72 ± 4; 55 ± 4	N* (p < 0.0001)	?	?	N	N	SAPS II	33 ± 3; 58 ± 4	2	N	N	N
Hotchkiss [56]	N/S	N/S	N	59	56, ?	N	N	-		1	N	N	Y
Delogu [63]	47 ± 17	'Matched’	N	?	'Matched’	N	N	ASA	I to II	1	Y	N	Y t
Pellegrini [59]	44 (20–83)	(18 to 60)	N	?	?	N	N	ISS	25 (9 to 59)	1	N	N	N
Delogu [64]	?	'Matched’	N	?	'Matched’	N	N	ASA	I to II	1	N	N	Y t
Hotchkiss [60]	18 to 46	?	N	90	?	N	N	ISS	N/S (9 to 50)	1	N	N	N
Hotchkiss [57]	N/S	N/S	N	65	?	N	N	-		1	N	N	Y
Sasajima [65]	62 (55 to 74); 49(37 to 58)		N		?	N	N	?	?	1	N	N	N
Sugimoto [66]	N/S		N	50		N	N	?	?	1	N	N	Y t

Age: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N*, not reported but we identified the significant p value from the original manuscript data. Severity of subject disease: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score [87]; ASA, American Society of Anesthesiologists Physical Status Classification System [85]; APACHE II: Acute Physiology and Chronic Health Evaluation II [83], APACHE III, Acute Physiology and Chronic Health Evaluation III [84]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was documented. A‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.‘Matched’, paper provided no details but stated the control population was matched to the study population.

Back to article page